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Sllmmal"y 
Adenosine deaminase binding protein (ADAbp)  is a cell surface glycoprotein that is expressed 
by normal melanocytes but not by melanoma, the malignant counterpart. ADAbp is specifically 
downregulated during malignant transformation of melanocytes. Recently, we have developed 
a system that progressively transforms melanocytes in vitro in defined steps. Transduction with 
v-Ha-ras oncogene followed by long-term culture leads to a cell phenotype and genotype that 
specifically mimics human melanoma. Loss of ADAbp expression occurred concomitantly with 
the emergence of growth factor independence and appearance of specific  chromosomal abnormalities. 
The cellular function of ADAbp has not been defined. To characterize ADAbp, the mature 110- 
kD form was purified from human kidney. Five tryptic peptides from purified human ADAbp 
revealed 100% homology to a serine protease, human dipeptidyl peptidase IV (DPP IV), also 
known as CD26. DPP IV activity was detected in lysates from human melanocytes and renal 
carcinoma cells but not melanoma cells, and DPP IV activity could be specifically isolated from 
melanocytes by binding to ADA or to $27 monoclonal antibody against ADAbp. These findings 
show that  ADAbp is a cell surface ectopeptidase  that is tightly regulated during neoplastic 
transformation of melanocytes. 
M 
elanoma is a neoplasm derived from cells of the melano- 
cyte lineage. Malignant transformation of melanocytes 
leads to progressive and profound alterations in cell pheno- 
type, manifested by invasion into surrounding tissues, dys- 
regulated growth, and metastasis. Careful clinical and patho- 
logical analyses have led to the description  of lesional steps 
in transformation and progression of human melanoma (1). 
Because of the accessibility of lesions that represent different 
stages in melanoma evolution, melanoma has become a useful 
paradigm to study progression  of human cancer. 
Some of the best characterized phenotypic changes observed 
during melanoma progression  come from the study of an- 
tigen expression. A broad assortment of antigens, including 
intracellular  and cell surface, have been defined on melano- 
cytes and melanoma. Most antigens  have been detected on 
both melanocytes and melanoma cells, and are presumably 
regulated during melanocyte differentiation. Several  molecules 
or epitopes have been identified that discriminate steps in mela- 
noma progression  (2, 3). Despite the profound phenotypic 
alterations that occur during steps of tumor progression, how- 
ever, it has been difficult to define qualitative changes (i.e., 
absence vs. presence) that absolutely distinguish normal cells 
in the melanocyte lineage from melanoma cells. Adenosine 
deaminase binding protein (ADAbp), 1 a plasma membrane 
glycoprotein consisting of 110-120-kD subunits  (4, 5), is a 
candidate for a molecule that is specifically regulated during 
melanocyte transformation and melanoma progression.  We 
have previously found that ADAbp is consistently expressed 
by melanocytes in vitro and in vivo but cannot be detected 
on melanoma cells (6), Furthermore, transformation of mel- 
anocytes in vitro extinguishes ADAbp expression (6, 7). The 
present studies were undertaken to further explore the link 
between ADAbp expression and transformation of melano- 
cytes. We show that ADAbp expression is lost as melanoma 
growth becomes independent of exogenous growth factors. 
ADAbp has been purified and shown to be indistinguishable 
from the cell surface serine protease, dipeptidyl peptidase IV 
(EC 3.4.14.5)  (DPP IV). 
Materials and Methods 
Reagents.  Con A-Sepharose, wheatgerm agglutinin (WGA)- 
Sepharose, and protein A-Sepharose  were obtained from Pharmacia 
1 Abbreviations used in this paper: ADAbp, adenosine deaminase binding 
protein; DPP IV, dipeptidyl peptidase IV; RAMPS, rabbit anti-mouse IgG 
protein A-Sepharose. 
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trophoresis molecular weight standards  were obtained from Bio- 
Pad Laboratories (Richmond, CA). Rabbit anti-mouse IgG was 
obtained  from  Cappel  Laboratories  (Durham,  NC).  Rabbit 
anti-mouse IgG protein A-Sepharose (RAMPS) was prepared from 
rabbit anti-mouse IgG and protein A-Sepharose. $27 and $4 mouse 
mAbs were purified from ascites of hybridoma-bearing mice by 
binding to protein A-Sepharose.  mAbs were >99% pure by SDS- 
PAGE.  Bovine adenosine deaminase  (ADA)  was  obtained from 
Boehringer-Mannheim Biochemicals (Indianapolis, IN). ADA was 
>90% pure by SDS-PAGE and was used to prepare Affigel affinity 
columns without further purification. Cell culture reagents were 
obtained from Gibco Laboratories (Grand Island, NY). Polyvinyli- 
dene difluoride membrane (PVDF, Immobilon-P) was obtained from 
Millipore (Bedford, MA). Nitrocellulose membrane was obtained 
from Scheicher & Schuell,  Inc.  (Keene,  NH).  [3H]Glucosamine 
was obtained from New England Nuclear (Boston, MA). Standard 
reagents and buffers were obtained from Sigma Chemical Co. (St. 
Louis, MO). Microtest plates were obtained from Robins Scientific 
(Sunnyvale,  CA). 
Cell Lines and Tissues.  Human melanoma and renal carcinoma 
cell lines were maintained in Eagle's MEM supplemented with 10% 
FCS, 0.1 mM nonessential amino acids, 100 U/ml penicillin,  and 
0.1 mg/ml streptomycin.  Normal human melanocyte cell lines were 
maintained in Eagle's MEM supplemented with 10% FCS, 0.1 mM 
nonessential amino acids, 10 ng/ml PMA, 1/~g/ml cholera toxin, 
and 10 #M isobutylmethylxanthine.  10W ras/early and 10W ras/late 
melanocyte cell lines were generated by infection of a human fore- 
skin melanocyte cell line, designated 10W, at passage 3 with mu- 
rine retrovirus carrying v-Ha-ras and pseudotyped with the am- 
photropic murine leukemia virus 4070A as previously described 
(8).  Cells  were passaged  with 0.1%  trypsin and 0.02%  EDTA. 
Normal human renal tissue  was obtained at the time of surgery 
from patients requiring nephrectomy for renal carcinoma. Tissue 
was stored at  -70~ 
Serologic Assays and Radioimmunoprecipitation.  Assay of surface 
membrane ADAbp was performed by mixed hemadsorption as pre- 
viously described (6). Indicator cells were prepared by conjugation 
of rabbit anti-mouse IgG to human red blood cells with 0.01% 
(wt/vol) chromium chloride. Assays were performed on cells grown 
in microtest plates. Target cells that were plated 2-3 d earlier were 
incubated with serial dilutions of mouse mAb $27 for i h at room 
temperature. Target cells were washed, and indicator cells were then 
added  for 30  rain.  Unbound  indicator cells  were removed by 
washing, and the percentage of target cells exhibiting red cell ro- 
settes  was  scored by light microscopy. 
Cell labeling, immunoprecipitation, and gel electrophoresis were 
carried out as previously described (6).  Cells  were labeled  with 
[3H]glucosamine  over 72  h  in  glucose-free Eagle's  MEM  con- 
taining 7.5 % dialyzed FCS. Lysates were immunoprecipitated with 
mAb $27 followed by 5 ng/ml protein A-Sepharose. Immunoprecipi- 
tates were analyzed by SDS-PAGE. 
Affinity Purification ofADAb  F  mAb $27 and ADA were cou- 
pled to Affigel-10 and Affigel-15, respectively, according to instruc- 
tions of the manufacturer. BSA was coupled to Affigel-15 for use 
as a control in experiments with ADA-Affigel.  Protein coupling 
was monitored by the absorbance of acidified aliquots (pH 1) at 
280 nm. In preparations used for bulk purification of ADAbp, pro- 
tein was coupled to Affigel at a concentration of 5-6 mg/ml of gel. 
Normal renal tissue was dissected free from fat and connective 
tissue.  Tissue was diced and then forced through a fine sieve in 
the presence of 6 vol of lysis buffer (50 mM Tris, pH 7.4, 1% NP- 
40, 10 #g/ml aprotinin, 1 #g/ml leupeptin,  and 1 #g/ml pepstatin). 
The lysate was incubated with gentle agitation for 1 h. All proce- 
dures were carried out at 4~  Debris was removed by centrifuga- 
tion for 30 rain at 2,000 g. Solid NaC1 was slowly added to a final 
concentration of 0.5 M while stirring the lysate. A 10x  concen- 
trated stock of CaC12 and MnC12 was  then added (final concen- 
tration, 1 mM Ca  2§ and Mn2§  High salt conditions were used 
during incubation with Con A-Sepharose to minimize nonspecific 
binding to the support matrix. The lysate was incubated with 5 ml 
of Con  A-Sepharose for 4  h  with  gentle  agitation.  The Con 
A-Sepharose was transferred to a column and washed with 20 vol 
of 50 mM Tris, pH 7.4, containing 0.1%  NP-40, 0.5 M  NaC1, 
1 mM CaC12, 1 mM MnC12, and 1 #g/ml aprotinin. The column 
was then washed with 10 vol of buffer containing 150 mM NaC1. 
Glycoproteins were batch eluted by incubation for 1 h with 10 ml 
of 10% c~-methyl-mannopyranoside  in 50 mM Tris, pH 7.4, con- 
taining 0.1% NP-40, 150 mM NaC1, 1 mM EDTA, and 2/xg/ml 
aprotinin. The eluted material was incubated with mAb S27-Affigel 
affinity matrix overnight. The Affigel was transferred to a column 
and washed with 20 vol of high salt buffer (0.5  M NaC1 in 50 
mM Tris, pH 7.4,  containing 0.1%  NP-40,  1 mM EDTA,  and 
1/zg/ml aprotinin), followed by 20 vol of low-salt buffer (150 mM), 
then with 10 vol of dilute buffer (5 mM Tris, pH 7.4, containing 
0.1% NP-40, 150 mM NaC1, and 1 #g/ml aprotinin). Bound pro- 
teins  were eluted in 0.5-ml fractions of 100 mM glycine buffer, 
pH 2.5, containing 150 mM NaC1 and 2 #g/ml aprotinin. Frac- 
tions were collected in 100 #1 of i  M Tris, pH 8.0 (final pH  = 
7.2). Aliquots of each fraction were analyzed by 7.5 % SDS-PAGE 
under reducing conditions. Gels were silver stained to visualize pro- 
tein. ADAbp-containing fractions were pooled. An aliquot was set 
aside for later purification by ADA-Affigel affinity matrix. The re- 
mainder of the ADAbp-containing fractions were precipitated by 
the addition of an equal volume of ice-cold acetone and stored over- 
night at  -20~  The precipitate was recovered by centrifugation 
and dissolved in sample buffer for SDS-PAGE. In parallel experi- 
ments,  renal  tissue  was  lysed  and  bound  overnight  to  WGA- 
Sepharose. Bound glycoproteins were eluted with buffer containing 
10% N-acetyl-glucosamine. Eluted material was incubated with 
mAb S27-Affigel and processed  as above. An aliquot of ADAbp 
was further characterized by binding to ADA-Affigel. After binding 
overnight, the Affigel was washed with 30 vol of 50 mM Tris, pH 
7.4, containing 0.1% NP-40, 0.5 M NaC1, and 1 mM EDTA, fol- 
lowed by low-salt buffer (150 mM NaC1). ADAbp was eluted with 
SDS-containing sample buffer and subjected  to electrophoresis on 
a 7.5% polyacrylamide gel under reducing conditions. Proteins were 
visualized  by silver stain. 
Because renal tissue  was not easily obtained, it was necessary 
to maximize the yield of ADAbp for use in amino acid analysis 
and sequence analysis of tryptic peptides. Material that did not bind 
to lectin under the stringent high-salt conditions described above 
was further purified by binding to mAb S27-Afftget affnity matrix 
and pooled with the ADAbp isolated  above. 
Amino Acid Analysis of  ADAbp.  An aliquot, representing 10% 
of the total mAb $27 affinity-purified  ADAbp, was  subjected  to 
electrophoresis  on  a  0.75-mm  thick  7.5%  polyacrylamide gel 
under reducing conditions.  ADAbp was  electrotransferred onto 
Immobilon-P membrane in 10 mM 3-cyclohexylamino-l-propane 
sulfonic acid (CAPS) buffer, pH 11.0, containing 10% methanol 
(9). Transfer was complete after 75 min at 50 V (0.5 A). ADAbp 
was visualized by staining with 0.2% Ponceau S in 1% acetic acid. 
The ADAbp band was excised, destained  in water, and allowed to 
air  dry.  Amino  acid  analysis  was  performed  at  the  Harvard 
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in 6 N HC1 for 24 h at 110~  Free amino acids were derivatized 
with phenylisothiocyanate and analyzed by HPLC (10). 
Trypsin  Digestion, HPLC Separation, and Microsequencing  of  ADA bp 
Peptides.  ADAbp,  affinity purified with mAb $27, was separated 
by SDS-PAGE and electrotransferred  onto nitrocellulose  membrane. 
The band at 110 kD (ADAbp) was excised. Subsequent processing 
was performed at the Harvard Microchemistry Facility. ADAbp 
was submitted to in situ digestion with trypsin (11), omitting the 
NaOH  wash. The resulting peptide mixture  was separated by 
narrow-bore HPI_C using a Vydac  C18 2.1  x  151Ymm  reverse-phase 
column  on a 1090 HPLC/1040 diode array detector (Hewlett- 
Packard Co., Palo Alto, CA). Optimum fractions from each pep- 
tide chromatogram were chosen based on differential UV absor- 
bance at 210, 277, and 292 nm, peak symmetry, resolution, and 
predictive column retention. Automated Edman degradation was 
performed on a protein sequencer (477A; Applied Biosystems,  Inc., 
Foster City, CA) by standard methods except that the reaction car- 
tridge temperature was raised  to 53~  during coupling with a com- 
mensurate decrease in R2 delivery and drydown time. Details of 
strategies for the selection of peptide fractions and their microse- 
quencing have been previously described (12). 
Demonstration of  DPP IV Activity.  Cells  grown in culture were 
washed five times with PBS, then removed from the culture flasks 
with a rubber policeman and resuspended in PBS. An aliquot was 
diluted into trypan blue and counted on a hemocytometer. Cells 
were collected by centrifugation at 2,000 g for 10 rain and lysed 
by incubation at 4~  for 30 min in 50 mM Tris containing 1% 
NP-40 and 20/xg/ml aprotinin. The volume of lysis buffer was 
adjusted so that the number of cells per microliter was equal for 
all samples. Lysates were incubated for 3 h with either 3.75/xg 
mAb ($27 or $4) or with no additions. A 20-/A pellet of RAMPS 
was then added to samples containing mAb and to control samples. 
Samples were incubated overnight at 4~  with rocking. RAMPS 
pellets were washed five times with cold 50 mM Tris, pH 7.4, con- 
taining 1% NP-40, then washed once with cold HzO. Antibody- 
antigen complexes  were dissociated  by rocking for 10 rain at room 
temperature with 100 mM glycine  buffer, pH 3.5, containing 0.1% 
NP-40. Samples were then subjected to electrophoresis on a 7.5% 
native polyacrylamide  gel (SDS and ~-mercaptoethanol omitted). 
Gels were stained for DPP IV activity by a modification of the 
method of Yoshimoto and Walter (13). Gels  were incubated  at room 
temperature for 30 rain in a solution of 0.5 mM glycyl-prolyl-4- 
methoxy-B-naphthylamide and  1.25 mg/ml tetrazotized  o-dia- 
nisidine in 0.2 M Tris, pH 7.4. Positive staining was indicated by 
an insoluble precipitate formed by the cleaved 4-methoxy-B-naph- 
thylamine and tetrazotized o-dianisidine.  In other experiments, ly- 
sates also were incubated overnight at 4~  with 40-/~1 pellets of 
either ADA-Affigel,  BSA-Affigel,  or with no additions (ADA and 
BSA were coupled to Affigel-15  at 5-6 mg/ml of gel). Affigel  pellets 
were washed and eluted as above. Samples were subjected to elec- 
trophoresis on a 7.5% native polyacrylamide gel and stained for 
DPP IV activity. 
The ability ofmAb $27 to bind to the same  protein as that bound 
by ADA-Affigel  was tested as follows. Lysates  of SK-RC-28 renal 
carcinoma cells were incubated with either 20 #g of mAb $27 or 
with no additions for 3 h at 4~  A 50-/A pellet of RAMPS was 
then added to each sample. Samples were incubated overnight at 
4~  with rocking. The samples were centrifuged to pellet the 
RAMPS, and the supernatants were recovered. Supernatants from 
lysates  incubated only with RAMPS were then incubated  overnight 
with either ADA-Affigel  or with BSA-Affigel.  Supernatant that had 
been preincubated  with mAb $27 and RAMPS was incubated over- 
night with ADA-Affagel.  Proteins bound to the RAMPS or Affigel 
were dissociated with glycine buffer as described above. 
Results 
Complete Neoplastic  Transformation of Melanocytes by v-Ha- 
ras  In  Vitro  Induces Loss  of ADAbp  Expression.  We  have 
reported that transduction and expression of  v-Ha-ras oncogene 
in cultured normal human diploid melanocytes can induce 
a subset of traits that distinguish melanoma from melano- 
cytes (6, 8). Long-term expression of v-Ha-ras results in com- 
plete neoplastic transformation, with mdanocytes acquiring 
all the phenotypic and genotypic characteristics  observed in 
malignant melanoma in vivo (7).  Transformation occurred 
in at least two phases and was associated with spontaneous 
chromosomal instability. We have found that extinction of 
ADAbp expression by v-Ha-ras expression in melanocytes oc- 
curred late in the transformation process, and correlated with 
a subset of traits that included PMA-independent growth, 
tumorigenicity in nu/nu mice, and the development and reten- 
tion of specific chromosomal markers. 
The v-Ha-ras  oncogene was introduced into a passage 3 
human foreskin melanocyte culture, designated 10W, by a 
murine retrovirus carrying the v-Ha-ras oncogene and pseu- 
dotyped with amphotropic murine leukemia virus (MuLV) 
4070A.  In the early phase of growth,  10W ras/early  cells 
changed morphology, were hyperploid, and acquired anchor- 
age-independent  growth, but remained dependent on the exo- 
genous growth stimulator PMA for proliferation and sur- 
vival (8).  10W ras/early  cells continued to express ADAbp 
(Fig.  1, A  and B), and the level of cell surface expression  of 
ADAbp was similar to 10W parental cells (data not shown). 
At '~6 mo, loci of cells with distinct morphology appeared 
in the 10W ras/early culture. The 10W ras/late cell line, es- 
tablished from these loci, grew independently of exogenous 
growth factors in the culture medium and acquired specific 
Figure  1.  Expression  of ADAbp by 10W melanocytes  transduced  with 
v-Ha-ras. (A) Mixed  hemadsorption  assay  of cell surface  ADAbp expression 
using mAb $27 (initial  mAb concentration,  30 #g/ml). (B) Radioimmu- 
noprecipitation  of  ADAbp by mAb $27 from  lysates  of 10W m/early and 
10W ras/late melanocytes  metabolically  labeled with [3H]glucosamine. 
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nomas (i.e., iso 6p, iso 9q, and del lp) (7).  10W ras/late cells 
did not express ADAbp at the cell surface, and ADAbp syn- 
thesis was not detected by metabolic labeling (Fig.  1, A  and 
B). Thus, in this in vitro model of sequential neoplastic trans- 
formation of melanocytes, loss  of ADAbp expression cor- 
responded to acquisition of independence from exogenous 
growth factors and was associated with specific chromosomal 
alterations. 
Purification of  Human ADAbtx  ADAbp was purified from 
normal human tissue to determine its identity and possible 
function. Kidney is the most abundant  source of ADAbp, 
and was used because of difficulty in obtaining large quanti- 
ties of melanocytes for ADAbp purification.  The structure 
of ADAbp derived from kidney and melanocytes cannot be 
distinguished: ADAbp from both cell types has identical mo- 
lecular mass and expresses three distinct epitopes recognized 
by different mAbs against ADAbp (mAbs $6, $23, and $27) 
(6, 14, 15). 
Initially, an NP-40 lysate was enriched for glycoproteins 
by lectin affinity purification. This fraction was then affinity 
purified using mAb $27,  directed against ADAbp, coupled 
to an Affigel support matrix. Proteins eluted from the mAb 
$27  affinity column included a prominent band present at 
"~110 kD, corresponding to the known molecular mass of 
ADAbp (Fig. 2). A second band was present at 132 kD, and 
a broad region of staining was observed between 97 and 110 
kD. Affinity-purified fractions were pooled and further en- 
riched by ADA-Affigel affinity matrix. The 110- and 97-110- 
kD bands were bound by ADA-Affigel (Fig.  2).  Thus,  the 
110-kD band was characterized as a glycoprotein that bound 
both to mAb $27  and ADA, and was felt to represent the 
mature, processed form of ADAbp. The broad band at 97-110 
kD also bound to mAb $27 and ADA, and could represent 
partial breakdown products, intermediate forms, or alterna- 
tively processed forms of ADAbp. The 132-kD protein band 
that copurified with the 110-kD  band on mAb S27-Affigel 
did not bind to ADA. We speculate that the 132-kD band 
is a distinct protein associated with ADAbp in the cell mem- 
brane, although it could represent an alternatively processed 
form of ADAbp that  does not bind to ADA. 
Sequences  of Tryptic  Peptides  of  ADAbp and Amino Acid Anal- 
ysis.  Five tryptic peptides (totaling 63  amino acids)  were 
sequenced from the 110-kD band of ADAbp. Search of the 
EMBL/GenBank databases  revealed  100%  identity (63/63 
amino acids) to human CD26,  recently reported by Tanaka 
et al. (16). CD26 is also known as DPP IV (17). There was 
87% amino acid homology (55/63 amino acids) to sequences 
within a cDNA-encoding DPP IV isolated from rat liver (Fig. 
3)  (18). Peptides  corresponded  to  amino  acid  positions 
259-267,  374-382,  493-522,  598-611,  and 659-669 in the 
putative extracellular domain of human CD26/DPP IV, de- 
termined from the deduced polypeptide sequence of human 
ADAbp described by Tanaka  et  al.  (16). 
The 110-kD band was also analyzed for amino acid com- 
position,  deduced from the known molecular mass of the 
ADAbp core polypeptide (85  kD [5])  (Table  1).  We com- 
pared the amino acid composition of human and rat DPP 
IV to human ADAbp, revealing nearly identical patterns (Table 
1).  The 97-110-kD  region was also  analyzed by excising a 
band at m97 kD. The 97-kD band had an amino acid com- 
position that was similar to that of the 110-kD  form (Table 
1), supporting the identity of core polypeptides for 97- and 
110-kD forms. Variations in composition of individual amino 
acids could be attributed to protein yields. Derivatized amino 
acids from the 97-kD protein (from 0.2/~g)  yielded peaks 
approximately threefold higher than background noise com- 
pared with data generated from higher yields for the 110-kD 
protein (1.7 #g). For example, glycine yielded a higher value 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Aia-Gly-Ala-Val-Asn-Pro-Thr-Val-Lys 
Human  ADAbp:  Ile-Ile-Ser-Asn-Glu-Glu-Gly-Tyr-Arg 
Human  DPP  IV:  ......... 
Rat  DPP  IV:  Tyr  ....  Tyr  Lys  Glu  Met 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Val-Leu-Glu-Asp-Asn-Ser-Ala-Leu-Asp-Lys- 
Met-Leu-Gln-Asn-Val-Gln-Met-Pro-Ser-Lys 
Asp  -  -  - 
Figure 2.  Purification  of ADAbp from 
normal human  renal  tissue. Lysates,  enriched 
for glycoproteins  by lectin affinity  purifica- 
tion, were affinity  purified  using mAb $27 
bound to an Affigel  support matrix (/eft). 
Affinity-purified  fractions  were pooled and 
further enriched  by binding to ADA-Affigel 
affinity matrix (right). Eluted material was 
subjected  to 7.5% SDS-PAGE  under  reducing 
conditions. Proteins  were  visualized  by silver 
stain. ADAbp is seen as a 110-kD band. 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Leu-Gly-Thr-Phe-Glu-Val-Glu-Asp-Gln-Ile 
Leu  Glu  - 
Glu-Ala-Ala-Arg 
Human  ADAbp: 
Human  DPP  IV: 
Rat  DPP  IV: 
Trp-Glu-Tyr-Tyr-Asp-Ser-Val-Tyr-Thr-Glu-Arg 
Figure 3.  Amino  acid  sequence  (three-letter  code)  of  five  human  ADAbp 
peptides compared  with human  DPP IV and rat DPP IV. Identical  amino 
acids are indicated  by dashes. 
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ADAbp with That of Human 97-kD Band, Human DPP IV, 
and Rat DPP IV 
Human  Human  Human  Rat 
ADAbp  97  kD  DPP IV  DPP  IV 
ALA  46  37  40  47 
ARG  37  29  30  29 
ASN  40  34 
ASP  46  46 
ASX  113  95 
CYS  ND  ND  12  13 
GLN  30  33 
GLU  40  41 
GLX  82  84 
GLY  53  117  43  40 
HIS  23  13  19  21 
ILE  39  22  49  46 
LEU  57  38  62  63 
LYS  48  41  40  44 
MET  7  0  15  14 
PHE  28  18  31  31 
PRO  22  16  29  30 
SER  68  79  64  66 
THR  60  35  50  50 
TRP  ND  ND  21  21 
TYR  44  31  56  50 
VAL  47  27  49  48 
in the 97- than 110-kD protein, presumably due to contami- 
nation  from glycine in the SDS-PAGE buffer.  Methionine, 
which is only moderately stable during acid hydrolysis, was 
completely destroyed in the 97-kD protein and >50%  was 
destroyed in the 110-kD protein, based on comparison with 
derived human  DPP  IV  amino  acid  sequence. 
Purified ADAbF  Has  Dipeptidyl Dipeptidase IV Activity. 
DPP  IV is a  serine protease that  cleaves the  NH2-terminal 
dipeptide X-Pro or X-Ala (19). DPP IV ectopeptidase activity 
was tested in lysates from human melanocyte and melanoma 
cell lines and compared to lysates from the human renal car- 
cinoma cell line SK-RC-28.  Melanocyte and  SK-RC-28  ly- 
sates exhibited an identical band of DPP IV activity that could 
be  specifically  precipitated  by  mAb  $27  directed  against 
ADAbp  (Fig.  4  A).  No  activity was  detected in lysates of 
three melanoma cell lines (Fig. 4 A). DPP IV activities from 
the FS135 melanocyte cell line and the SK-RC-28 renal carci- 
noma cell line were specifically bound by ADA-Affigel affinity 
matrix, but not by BSA-Affigel (Fig. 4 B). The resultant band 
of DPP IV activity was identical to that immunoprecipitated 
by mAb $27 (Fig. 4 B).  In experiments with SK-RC-28,  it 
was further shown that preincubation of lysates with mAb 
$27 could deplete DPP IV activity precipitated by ADA-Affigel, 
establishing  that DPP IV activity bound by mAb $27 was 
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Figure 4.  ADAbp possesses DPP IV activity. (,4) Lysates  from three 
melanocyte  cell lines (FS133, FSD5, FS138)  and a renal carcinoma  cell line 
(SK-RC-28) were immunoprecipitated  with mAb $27. Controls were in- 
cubated with RAMPS. Lysates  or immunoprecipitates  were subjected to 
7.5% native PAGE and stained for DPP IV activity. Lysates  from three 
melanoma cell lines (SK-MEL-239,  SK-MEIr  SK-MEL-23),  melano- 
cytes, and renal carcinoma were analyzed for activity without prior im- 
munoprecipitation. Lysates  from melanocyte  and renal carcinoma  cell lines 
contained the equivalent of 4.5  x  10  s cells/lane. Lysates  from melanoma 
cell lines contained the equivalent of 1.1  x  106 cells/lane. (B) Lysates  from 
FS135 and SK-RC-28  were immunoprecipitated  with mAb $27 or affinity 
purified  with ADA-Affigel.  Controls were incubated with either RAMPS 
or BSA-Affigel.  Lysates  contained the equivalent of 6.2  x  10  s cells/lane. 
(C) Lysates from SK-RC-28 were preincubated with RAMPS, with or 
without mAb $27, and then affinity  purified  with ADA-Affigel.  Controls 
were preincubated with RAMPS and then incubated with BSA-Affigel. 
Lysates  contained the equivalent of 2.0  x  106 cells/lane. ADA-Affgel,  in- 
cubation with RAMPS followed  by ADA-Affigel;  ADA(.S27),  incubation 
with RAMPS followed by ADA-Affigel; BSA-Afligel, incubation with 
RAMPS followed  by BSA-Affigel. (D) Lysates  from SK-RC-28 were im- 
munoprecipitated with either mAb $27 or $4. Controls were incubated 
with RAMPS. Lysates  contained the equivalent of 6.3  x  105 cells/lane. 
identical to DPP IV bound by ADA (Fig. 4 C).  To control 
for possible nonspecific binding of DPP IV activity during 
immunoprecipitation of  plasma membrane proteins, SK-RC-28 
lysates were incubated  with  mAb  $4  against  gp160,  a  cell 
surface glycoprotein also present on SK-RC-28 (14). Incuba- 
tion with mAb $4 did not result in coprecipitation of DPP 
IV  activity (Fig.  4  D). 
Discussion 
ADAbp is a cell marker whose expression is not restricted 
to a specific lineage or particular stage of differentiation within 
a lineage. Rather, the regulation and function of ADAbp must 
be considered within frames of reference, depending on cell 
type. ADAbp was originally characterized as a surface mem- brane glycoprotein expressed on a variety of secretory  and 
absorptive epithelia (20, 21), fibroblasts (4), T lymphocytes 
(22),  and melanocytes (6). Our interest in ADAbp has fo- 
cused on its expression in normal melanocytes and its exqui- 
site regulation during melanocyte transformation. 
We have found that ADAbp is identical or analogous to 
CD26 and DPP IV, based on enzymatic characteristics  and 
peptide sequences. In retrospect, the three markers, ADAbp, 
CD26, and DPP IV, are indistinguishable with regard to pat- 
terns of expression in tissues (23) and biochemical properties 
(e.g.,  masses of mature forms [5, 16, 18] and formation of 
dimers [24, 25]).  Human ADAbp and CD26/DPP IV are 
100% identical in five peptide regions ranging over approxi- 
mately two-thirds of the CD26/DPP IV protein. Further- 
more, ADAbp and CD26/DPP IV have core polypeptides 
with the same apparent mass (5, 16, 18), supporting the no- 
tion that ADAbp and CD26/DPP IV are encoded by the 
same gene, although this does not formally rule out the pos- 
sibility that ADAbp could be encoded by a homologous gene. 
The derived amino acid sequence of human CD26 has re- 
cently been reported, and predicts a type II transmembrane 
molecule (16). CD26 cDNA encodes a potential signal se- 
quence, followed by a large 738-amino acid extracellular do- 
main (containing 10 possible Asn-linked glycosylation sites 
and a cysteine-rich region) on the carboxyl side of the puta- 
tive transmembrane domain, and a short six-amino acid cy- 
toplasmic domain (16). Of particular interest, the peptide se- 
quence Gly-Trp-Ser-Tyr-Gly  at amino acid positions 627-631 
of human CD26 is a potential catalytic  site for serine pro- 
teases and esterases (26). 
ADAbp, DPP IV, and CD26 have each been characterized 
within the context of specific cell and tissue types. For in- 
stance, ADAbp is expressed on discrete subsets of epithelial 
cells in kidney tubules (21), and ADAbp in colon carcinoma 
cells is regulated according to the state of cellular differentia- 
tion (27). Within the T lymphocyte lineage, CD26 has been 
defined as a marker of activated T  cells (16, 28).  A list of 
potential functions is equally complex. ADAbp on epithelial 
cells has been defined by binding to ADA; DPP IV in liver, 
kidney, bowel, and other tissues has been detected by ectopep- 
tidase activity, and CD26 on T cells plays a putative role in 
signal  transduction (16) but also binds to collagen (29). 
Within  the  melanocyte lineage,  ADAbp  expression  is 
specifically extinguished during malignant transformation and 
tumor progression, without regard to stage of melanocyte 
differentiation (6, 7). ADAbp is a candidate for a gene product 
that is specifically downregulated or altered during neoplastic 
transformation. Thus, ADAbp could suppress the neoplastic 
phenotype in melanoma cells, based on the strong correla- 
tion between malignant phenotype and ADAbp regulation. 
This view fits a paradigm for neoplasia, where losses or defects 
of cell function have been implicated increasingly in the patho- 
genesis of many (if not most) human cancers. Gene products 
of this type stand in contrast to dominant acting oncogenes 
defined originally in tumor viruses. The tumor suppression 
phenomenon has been defined genetically by: (a) somatic cell 
hybrids or by transfer of chromosomes, parts of chromosomes, 
or spedfic genes into tumor cells (30, 31); (b) discovery of 
homozygous recessive mutations in certain hereditary cancers 
(e.g.,  Wilm's tumor [32] and retinoblastoma [33]); and (c) 
nonrandom deletions, alterations, or mutations at defined loci 
(e.g., p53 [34]) in human cancers, with presumed associated 
defects in gene function. Genetic approaches  have not yet 
defined recessive oncogenes in human melanoma, although 
several candidate regions on chromosomes 1, 6, and 9 have 
been identified (35). Studies using somatic cell hybrids have 
tentatively assigned the genes encoding both ADAbp (36) 
and DPP IV (37) to chromosome 2, a chromosome that is 
altered in •35%  of melanoma specimens (35). Gross altera- 
tions in chromosome 2 probably occur during melanoma 
progression rather than as early events in melanocyte trans- 
formation, based on inconsistent alterations in chromosome 
2 in different metastases within the same patient and the lack 
of chromosome 2 changes in potential precursor lesions of 
melanoma (35). The relationship between melanoma progres- 
sion and alterations in chromosome 2 are consistent with our 
observations in vitro that loss of ADAbp expression is cor- 
related with specific steps in melanoma progression. Notably, 
a specific subset of melanomas derived from the uvea of the 
eye have shown specific, nonrandom allelic losses in chromo- 
some 2 (38). 
We have been able to induce loss of ADAbp expression 
in melanocytes in vitro in two systems: by transfection with 
Ha-ras followed by long-term culture, and by repeated pas- 
sage in the presence of isobutylmethylxanthine  (6, 7). In both 
cases, downregulation of ADAbp expression coincided with 
the emergence of growth factor independence, while other 
traits characteristic  of melanocyte transformation, such as 
anchorage-independent growth, loss of contact inhibition, 
induction of class II MHC  antigens, and upregulation of 
GD3 ganglioside, did not correlate with the loss of ADAbp 
expression.  These observations  suggest that ADAbp might 
function to regulate cell growth, perhaps through the degra- 
dation of crucial growth factors. This proposed function for 
ADAbp on melanocytes is based on the observed biological 
properties of DPP IV, which hydrolyzes the carboxy-terminal 
side of dipeptide sequences, with a preference for proline at 
the second residue but also recognizing alanine at a lower 
efficiency. DPP IV is the primary enzyme responsible  for 
cleavage and inactivation of serum growth hormone-releasing 
hormone (39). Potential cleavage sites exist in the matrix com- 
ponent collagen and the cytokines IL-1B, I1_,2, and GM-CSF 
(28). Interestingly, a possible cleavage site also exists in ADA, 
which has an amino-terminal Met-Ala  (40). 
A model relevant  to DPP IV expression  on melanocytic 
cells has been proposed for another cell surface peptidase, 
CD10/neutral endopeptidase 24.11, in small cell lung cancer 
(SCLC).  CD10 is a metalloendopeptidase that hydrolyzes a 
number of natural peptides, including atrial natriuretic factor, 
angiotensins 1 and 2,  substance P, endothelin, bradykinin, 
oxytocin, and Leu- and Met-enkephalins (41). CD10, which 
is expressed at low levels on SCLC, cleaves potential auto- 
crine growth factors for SCLC, including bombesin- and 
gastrin-releasing peptide (42). CD10 can inhibit proliferation 
1140  Characterization of Adenosine  Deaminase Binding Protein of growth factor-dependent  SCLC cells,  and inhibition  of 
CDIO activity can reverse this block (42). 
An interesting potential substrate for DPP IV is basic fibro- 
blast growth factor (bFGF), based on reported amino-terminal 
peptide sequences (43). Although there is no evidence that 
DPP IV cleaves bFGF, at least one form of purified bFGF 
has an amino-terminal  sequence (i.e.,  Pro-Ala-Leu-Pro) that 
provides a substrate for two successive rounds of proteolysis 
by DPP IV. Basic FGF fulfills criteria as an autocrine growth 
factor for melanoma:  (a) exogenous bFGF can stimulate the 
growth of melanocytes in vitro (44); (b) melanoma cells ex- 
press both bFGF and its receptor (45-47); (c) antibodies against 
bFGF have been used to inhibit  melanoma cell growth in 
vitro (48); (d) transfection of melanoma cells with antisense 
oligonudeotides against bFGF can inhibit melanoma prolifer- 
ation (49); and (e) mdanocytes transfected with bFGF cDNA 
grow independently of exogenous growth factors, although 
they form only benign, not invasive,  tumors when injected 
into  nude  mice  (50).  Thus,  expression  of bFGF  alone  is 
insufficient to confer a full malignant phenotype, but rather 
appears  to represent  a critical  step in a sequence necessary 
for full neoplastic transformation.  In the lOW melanocyte 
system, bFGF transcripts were detected in both 10W ras/early 
and 10W ras/late cells, but not parental  lOW calls (7).  In- 
terestingly, both ADAbp and CDIO were expressed by pa- 
rental 10W cultures and by 10W ras/early cells, which main- 
tained only a partially transformed phenotype and required 
exogenous growth factors for survival. However, expression 
of both peptidases was extinguished in the fully transformed 
lOW ras/late  cell strain  (7). 
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